Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (37)

I-02Donghwan Lee

Quantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD)

Wednesday 10:15-11:45

I-05Annabelle Lemenuel Diot

Identification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model

Wednesday 10:15-11:45

I-14

Refining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model)

Wednesday 10:15-11:45

I-28Enrica Mezzalana

A Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases.

Wednesday 10:15-11:45

I-35Ronald Niebecker

Modelling of Anti-Drug Antibodies Directed Against a Monoclonal Antibody

Wednesday 10:15-11:45

I-51

Mathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement Therapy

Wednesday 10:15-11:45

I-62Hyerang Roh

Quantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosin

Wednesday 10:15-11:45

I-68Vargo Ryan

Comparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for Cmax

Wednesday 10:15-11:45

II-01Teijo Saari

Significant changes in pharmacokinetics of sufentanil during target controlled infusion of sufentanil for cardiac anaesthesia.

Wednesday 15:10-16:40

II-14Hanna Silber Baumann

Population pharmacokinetics of cyclosporine A in cats

Wednesday 15:10-16:40

II-16Nicolas Simon

A joint PK/PD-PD model of levodopa in patients with Parkinson’s disease: Motor effect and Movement disorder

Wednesday 15:10-16:40

II-17

Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives

Wednesday 15:10-16:40

II-23David Stepensky

Inter-patient variability of local vs. systemic effects of TNF-α-neutralizing antibodies in rheumatoid arthritis

Wednesday 15:10-16:40

II-24Jasper Stevens

Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients

Wednesday 15:10-16:40

II-25Elisabet Størset

Population pharmacokinetics of tacrolimus to aid individualized dosing in kidney transplant recipients

Wednesday 15:10-16:40

II-26

A Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy

Wednesday 15:10-16:40

II-28Herbert Struemper

Target-mediated clearance of ofatumumab: a tale of different disease states

Wednesday 15:10-16:40

II-31Takeshi Tajima

Mechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers

Wednesday 15:10-16:40

II-33David Ternant

A model predicting expected infliximab serum concentrations using only dose and time since last infusion

Wednesday 15:10-16:40

II-49

Population Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab

Wednesday 15:10-16:40

II-54

Population pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients

Wednesday 15:10-16:40

II-61Stefano Zamuner

PK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect.

Wednesday 15:10-16:40

II-62Stefan Zeiser

Population PK Modeling of Dapivirine Released from Vaginal Rings

Wednesday 15:10-16:40

III-07Jacqueline Anderson

PKPD modelling of human chlorpyrifos poisoning

Thursday 10:05-11:35

III-10Daren Austin

A closed-form solution set-point model of treatment response in multiple diseases

Thursday 10:05-11:35

III-11Nicolas Azzopardi

Modelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT)

Thursday 10:05-11:35

III-16Aliénor Bergès

Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis

Thursday 10:05-11:35

III-17Tarjinder Sahota

A mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers

Thursday 10:05-11:35

III-30Thierry Buclin

Monitoring Blood Prostate-Specific Antigen (PSA) after Radical Prostatectomy

Thursday 10:05-11:35

III-34Yu-Jung Cha

Population Pharmacokinetics of Etanercept in Healthy Korean Male Volunteers

Thursday 10:05-11:35

III-60

Joint modelling of the placebo response and the dropout mechanism using clinical data from a trial performed in patients suffering from major depressive disorder

Thursday 10:05-11:35

III-69Martin Fink

Population pharmacokinetic analysis of robenacoxib in dogs with chronic osteoarthritis

Thursday 10:05-11:35

IV-04Nicolas Frey

Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis

Thursday 15:00-16:30

IV-09Samira Garonzik

Development of PK/PD Models to describe Pharmacokinetics and Biomarker Responses for Dovitinib (TKI258)

Thursday 15:00-16:30

IV-10Peter Gennemark

Experimental design based on mechanistic mathematical modeling of body composition and energy turnover

Thursday 15:00-16:30

IV-12Massimiliano Germani

Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole.

Thursday 15:00-16:30

IV-38Daniel Hovdal

A mechanism-based population model for estimation of system parameters, vehicle effects and drug-induced body weight changes in diet induced obesity mice

Thursday 15:00-16:30